ID
43569
Beskrivning
Study ID: 101468/197 Clinical Study ID: SKF-101468/197 Study Title:An open study to compare the PK and tolerability of ropinirole administered as 5 different new formulations with the standard, marketed formulation in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication : Restless Legs Syndrome
Nyckelord
Versioner (3)
- 2017-09-11 2017-09-11 -
- 2017-09-12 2017-09-12 -
- 2021-09-20 2021-09-20 -
Uppladdad den
20 september 2021
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
visit period 1,2,3 & 4 plasma drug assay PK and tolerability of ropinirole as 5 new formulations 101468/197
visit period 1,2,3 & 4 plasma drug assay PK and tolerability of ropinirole as 5 new formulations 101468/197
Beskrivning
Date and Time
Alias
- UMLS CUI-1
- C1264639
Beskrivning
plasma assay sample
Alias
- UMLS CUI-1
- C0444263
- UMLS CUI-3
- C0013227
- UMLS CUI-4
- C0683150
Beskrivning
time relative to dosing
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0439564
- UMLS CUI [1,2]
- C3469597
- UMLS CUI [1,3]
- C0304229
Beskrivning
date
Datatyp
date
Alias
- UMLS CUI [1]
- C0011008
Beskrivning
time
Datatyp
time
Alias
- UMLS CUI [1]
- C0040223
Beskrivning
comment
Datatyp
text
Alias
- UMLS CUI [1]
- C0947611
Beskrivning
initials
Datatyp
text
Alias
- UMLS CUI [1]
- C2986440
Similar models
visit period 1,2,3 & 4 plasma drug assay PK and tolerability of ropinirole as 5 new formulations 101468/197
C3469597 (UMLS CUI [2])
C0013227 (UMLS CUI-3)
C0683150 (UMLS CUI-4)
C3469597 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])